GemPharmatech Co Ltd
SSE:688046
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (4.4), the stock would be worth ¥16.62 (20% downside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 5.5 | ¥20.66 |
0%
|
| 3-Year Average | 4.4 | ¥16.62 |
-20%
|
| 5-Year Average | 4.8 | ¥17.82 |
-14%
|
| Industry Average | 6.9 | ¥25.67 |
+24%
|
| Country Average | 2.8 | ¥10.33 |
-50%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
¥3.4B
|
/ |
Oct 2025
¥752.7m
|
= |
|
|
¥3.4B
|
/ |
Dec 2025
¥799.3m
|
= |
|
|
¥3.4B
|
/ |
Dec 2026
¥935.9m
|
= |
|
|
¥3.4B
|
/ |
Dec 2027
¥1.1B
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
G
|
GemPharmatech Co Ltd
SSE:688046
|
4.2B CNY | 5.5 | 34.2 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
936.1B USD | 327.8 | 3 881 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
173.3B USD | 3.9 | 25.9 | |
| US |
|
Danaher Corp
NYSE:DHR
|
126.5B USD | 5.1 | 34.4 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 18.1 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
331.7B CNY | 7.1 | 16.8 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
32.5B CHF | 5 | -119.8 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
31.5B USD | 4.6 | 25.1 | |
| US |
|
Waters Corp
NYSE:WAT
|
28.7B USD | 9.5 | 46.6 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
26.6B USD | 1.7 | 19.8 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
25.2B USD | 6.4 | 29.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.5 |
| Median | 2.8 |
| 70th Percentile | 5.4 |
| Max | 5 034 353.9 |
Other Multiples
GemPharmatech Co Ltd
Glance View
GemPharmatech Co., Ltd. engages in research and development, manufacture, and sale of experimental mouse models. The company is headquartered in Nanjing, Jiangsu and currently employs 1,342 full-time employees. The company went IPO on 2022-04-25. The firm uses gene-editing and other technologies to produce mouse models. The firm also involves in the business of customized model breeding, drug efficacy analysis, and model customization. The Company’s products are mainly used to satisfy the experimental demands in the fields of gene function cognition, disease mechanisms analysis, drug target discovery, and other fundamental researches.
